# National HIV Behavioral Surveillance (NHBS): PWID 2024





- What is NHBS?
- PWID in Philadelphia
- Formative Assessment
- Sample Characteristics
- Changes since 2022
- Programmatic Implications
- Comments from field staff

#### NHBS Team

- Principal Investigators: Kathleen Brady, Tanner Nassau
- HIV Surveillance Manager: Erika Solomon
- NHBS Project Coordinator: Lyric Kleber
- Field Coordinators: Andrea Harrington, Antonio McFadden
- Interviewers/testers: Dana Brown, Hunter Schreiner, Tiffany Nakajima, Dolicia Dobbs, Shannon Driggins, Tulie Reddick
- Support Staff: Ralph Nixon, Bianca Black, Action Wellness, TB Clinic



### NHBS Overview


### National HIV Behavioral Surveillance (NHBS)

- Rotating annual survey in 3
   populations at increased risk san Francisco
   for HIV acquisition: MSM,
   PWID, heterosexually active
   persons at increased risk for
   HIV infection
- Sex and drug using behaviors that increase risk for exposure to HIV, HIV testing, access to prevention and other services




### HIV Outbreak Among PWID, 2018-2023

- During 2023, there were 27 new HIV diagnoses among PWID
- In total, there have been 365 cases of HIV among PWID since identifying an outbreak in 2018.




### HIV Outbreak Among PWID, 2018-2023

• Among outbreak-related cases, the majority are between the ages of 30-49 at diagnosis (63.0%), assigned male at birth (70.4%), and NH White (52.3%).



### Newly Diagnosed HIV - 2023




Highest **rates** of new diagnoses:

- MSM (1,673.8 per 100,000), followed by PWID (100.7), and atrisk heterosexuals (30.2)
- NH Black (38.7 per 100,000) and Hispanic/Latinx (25.9) people compared to NH White (11.3) people

#### HIV Prevalence Rates

- Overall HIV prevalence rate of 1,133.4 per 100,000
- HIV prevalence among PWID is nearly 5 times that of the overall population



### Trends in overdoses

# Philadelphia sees a decline in drug overdose deaths among residents for the first time in 5 years, data show

Drug overdose deaths among Philadelphians have risen every year since 2018, but preliminary numbers for 2023 show a drop.

By Nicole Leonard · October 2, 2024

Data from the Philadelphia Department of Public Health show that an estimated 1,122 residents died from drug overdoses in 2023. It's a small drop from the 1,207 confirmed deaths that occurred the previous year.

 Community and professional key informant interviews, focus groups, and field observations

- <u>Network findings</u>: large, geographically bound networks with connections across race/ethnicity and gender
  - Youth (<30) tend to interact with other youth</li>
  - Preferences for other using similar types of drugs

Implications: Seeds need to be geographically diverse, younger, and inject different types of drugs


- Barrier findings
  - Length of interview
  - Respect for participants
  - Policing/police presence
  - Disruption of networks (RDS)
  - Unstable phone access

Implications: Protocols, trainings, and field sites need to focus on ways to minimize barriers

- Drug use patterns
  - Xylazine ("tranq dope") predominant → leads to stimulant use to counteract sedative effects
    - Possibly unintentional polysubstance use
    - Injection wounds, multiple injection sites
  - Increased smoking/snorting
  - Possibly more reuse/sharing of injection equipment due to distribution changes

Implications: While syringe distribution may be decreasing, frequency of injection may also be decreasing

# Sample Characteristics




### Socioeconomic Indicators


	N (%)	
Household Income < \$10,000	277 (64.3)	
Unemployed	299 (68.7)	
< High School education	109 (25.3)	
Recent housing instability	319 (74.0)	
Currently unhoused	224 (52.0)	
Recent incarceration	110 (25.5)	

# Drug Use Characteristics

#### Primary drug injected



#### Frequency of Injection




# Drug Use Characteristics

Recent Fentanyl Use: 86.3% Frequency of fentanyl use:


- More than once a day: 83.1%
- Once a day: 6.4%
- More than once a week: 5.0%
- Once a week or less: 5.3%

Formative: Fentanyl test strips may not be widely used because they cannot **quantify** the amount of fentanyl

#### Daily/more than daily non-injection drug use by year




#### Daily/more than daily non-injection drug use by year




# Healthcare Access

Insured	412 (94.7%)
Medicaid	380 (92.2%)
Seen a healthcare provider in the previous year	367 (84.6%)
Offered an HIV test	216 (62.4%)
Usual Source of Care	
Clinic/Health Center	120 (31.5%)
Doctor's Office	122 (32.0%)
Hospital Emergency room	124 (32.6%)
Lacked Healthcare due to cost	62 (14.3%)

# HIV and STI Testing




# Hepatitis C Testing




#### **Prevention Access**

#### PrEP Continuum

- PrEP awareness, discussions about PrEP, and PrEP usage were highest MSM
- At-risk heterosexuals & PWID reported the lowest levels of awareness, discussions about, and usage of PrEP.
- Discussions about PrEP with a medical provider in the last year were critically low across all groups.



# Prevention Access: Changes



# Implications 1

Housing instability, unemployment, and poverty are highly prevalent

- Structural barriers to HIV prevention/care and other services
- Increasing quality of life indicators in this population would increase access to prevention

# Implications 2

Increased contamination of dope with xylazine may be driving a shift toward smoking/snorting and injecting less frequently due to wound concern

- Harm reduction for infectious diseases
- May partly explain increases in syringe coverage
- Continued concern for overdose

# Implications 3

In the previous year, 1 in 4 HIV negative PWID had not been tested for HIV, and 9 in 10 had not discussed PrEP with a provider

- Recognize progress!
- Missed opportunity during an ongoing outbreak of HIV among PWID
- Missed opportunity around new PrEP options


# Medical Monitoring Project (MMP): 2018-2022 combined data



### MMP Overview


- Population-based surveillance system for information not always included in traditional HIV surveillance
  - Behaviors
  - Socioeconomic factors
  - Comorbidities
  - Quality of care
  - Barriers to care and viral suppression
  - Unmet needs

# Socioeconomic status of PWH in Philadelphia



	Prescription of ART	Fully Adherent to ART	Sustained Viral Suppression
Total	75.5%	58.9%	54.5%
Gender			
Cisgender Male	76.4%	58.7%	57.5%
Cisgender Female	71.5%	60.1%	47.4%
Transgender	86.5%	*	*
Sexual Orientation			
Lesbian or gay	79.3%	56.2%	67.8%
Heterosexual	76.2%	63.1%	48.4%
Race/Ethnicity			
NH-Black	73.6%	55.8%	49.6%
NH-White	87.0%	70.3%	75.9%
Hispanic/Latine	72.0%	58.7%	53.8%

# Reasons for missing ART doses



### Mental health and substance use

- <u>44.1%</u> of PWH in Philadelphia reported a mental, physical, or emotional disability
- <u>15%</u> of PWH in Philadelphia have symptoms of moderate or severe depression
- <u>Nearly 1 in 5</u> PWH in Philadelphia have symptoms of generalized anxiety disorder
- <u>43.3%</u> of PWH in Philadelphia reported noninjection drug use, most of whom reported marijuana use (<u>37.3%</u>)

### Unmet needs

- 15.2% of PWH who needed HIV case management did not get it
- 30.2% of PWH who needed dental care did not get it
- 26.9% of PWH who needed mental health services did not get them
- <u>25.0%</u> of PWH who needed drug or alcohol counseling/treatment did not get it

### Unmet needs

- 26.5% of PWH who needed transportation assistance did not get it
- <u>30.5%</u> of PWH who needed meal or food services did not get them
- <u>48.0%</u> of PWH who needed shelter or housing services did not get them

# Thank you!